Changes for ESAs.
Spalding
B J
BJ
D000068256:Darbepoetin alfa; D017277:Drug Approval; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011994:Recombinant Proteins; D014481:United States
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa